• MINEN
• biopsy
• hepatocellular
• liver
• neuroendocrine

• chromogranin A
• neuroendocrine tumor
• omental tumor
• synaptophysin

• Humans
• Omentum/pathology
• Omentum/surgery
• Female
• Neuroendocrine Tumors/pathology
• Neuroendocrine Tumors/diagnosis
• Neuroendocrine Tumors/surgery
• Aged
• Incidental Findings
• Peritoneal Neoplasms/pathology
• Peritoneal Neoplasms/diagnosis
• Peritoneal Neoplasms/surgery
• Colectomy
• Abdominal Pain/etiology
• Colorectal Neoplasms/diagnosis
• Colorectal Neoplasms/surgery

• chemotherapy
• genetic testing
• hepatocellular carcinoma
• neuroendocrine carcinoma
• rare disease

• hepatocellular carincoma
• neuroendocrine tumor
• rare tumor

• hepatocellular carcinoma
• neuroendocrine carcinoma
• surgical resection

• Chemotherapy
• Debulking operations
• Neuroendocrine carcinomas
• Transcatheter arterial chemoembolization

• FDG-PET/CT
• hepatocellular carcinoma
• liver
• neuroendocrine carcinoma

Hepatocellular carcinoma (HCC) can occasionally develop with other non-HCC cell types, either in a combined type or collision type. A collision tumor is defined as two histopathologically distinct tumors of the same organ lacking a clear transition zone. Hepatic collision tumors are rare. Among them, “hepatocellular carcinoma-hepatic neuroendocrine carcinoma” (HCC-NEC) collision tumors are especially rare and information about them is rarely published.

A 48-year-old man with typical findings of HCC underwent consecutive therapies, including radiofrequency ablation and embolization prior to resection. Diagnosis of the HCC-NEC collision tumor in the right liver and another HCC in the left liver was established following surgical resection. The patient displayed NEC metastasis following resection and succumbed to septicemia after 2 more rounds of chemotherapy. To our knowledge, this is the 25^th reported case of mixed HCC-NEC tumor. The rarity of HCC-NEC collision tumors and the absence of diagnostic criteria make it difficult to differentiate this condition from simple liver tumors, especially in patients with chronic liver disease.

Our case highlights the difficulty in accurately diagnosing HCC-NEC in the absence of histological evidence. The prognosis is poor for this condition, although ultrasound-guided liver biopsy can be helpful to establish a prompt diagnosis. Further accumulation of such cases could help establish an accurate diagnosis earlier. Early discovery of NEC may allow for better treatment strategies and better prognoses.

• Collision tumor
• Combined tumor
• Hepatocellular carcinoma
• Neuroendocrine tumor
• Case report

Combined tumors comprising large-cell neuroendocrine carcinoma and hepatocellular carcinoma have been rarely reported in the literature.

We report a case of a 73-year-old woman with chronic hepatitis B suspected to have a malignant hepatic mass (segment 3; size, 4.5 cm) and lymph node metastasis based on computed tomography and magnetic resonance imaging. Despite being Child-Pugh class A, esophageal varices were present. She underwent left lateral sectionectomy and lymph node dissection. Pathological examination revealed a collision tumor consisting of large-cell neuroendocrine (90%) and hepatocellular (10%) carcinomas. The combined carcinoma had metastasized to one of the three lymph nodes excised. The patient recovered without any postoperative complications and was discharged in good condition on postoperative day 13. Adjuvant chemotherapy was not performed. No recurrence occurred during a follow-up period of 24 mo.

To improve the therapeutic management of combined tumors in the liver, it is necessary to discuss each clinical experience and consider an appropriate method for the preoperative diagnosis and treatment.

• Hepatocellular carcinoma
• Neuroendocrine carcinoma
• Chronic hepatitis B
• Case report

• Gallbladder
• Gastrointestinal system
• Liver
• Mixed adeno neuroendocrine carcinoma
• Mixed neuroendocrine–nonneuroendocrine neoplasms
• Pancreas

• Adenocarcinoma
• Aged
• Biopsy
• Gastrointestinal Tract/pathology
• Humans
• Male
• Neuroendocrine Tumors/diagnosis

Primary hepatic neuroendocrine carcinomas (NECs) are extremely rare. The rate of recurrence after resection is extremely high, and the prognosis is poor. It is debatable whether chemotherapy or surgical resection is the optimal initial treatment for primary hepatic NECs. Therefore, selecting an appropriate therapeutic approach for patients with primary hepatic NECs remains clinically challenging. We present a case of primary hepatic NEC in a patient who developed recurrence after undergoing surgical resection.

A 78-year-old man with bone metastases of prostate cancer was referred to our department because of a solitary 66-mm tumor in the left lateral segment of the liver, which was detected on annual follow-up by computed tomography after prostate resection. A biopsy and preoperative diagnostic workup identified the lesion as a primary hepatic neuroendocrine carcinoma; therefore, left lateral segmentectomy was performed. Immunohistochemically, the tumor was positive for chromogranin A, synaptophysin, and CD 56, and the Ki-67 index was 40%. This neuroendocrine carcinoma was classified as a large cell type. Adjuvant chemotherapy with carboplatin + etoposide was initially administered a month after surgery. However, lymph node recurrence occurred 4 months after surgery, and the patient died of systemic metastases 15 months after surgical resection.

Due to the lack of availability of abundant quantities of relevant, high-quality data, there is no standard therapy for primary hepatic NECs. Selecting the most appropriate treatment for patients depending on several factors, such as the stage and differentiation of a tumor and a patient’s performance status and clinical course, is consequently preferred. More cases need to be studied to establish the best treatment strategy for primary hepatic NEC.

• Chemotherapy
• Primary hepatic neuroendocrine carcinoma
• Surgical resection

Neuroendocrine tumors usually originate from the neuroendocrine cells of gastrointestinal tract and their presence in the liver is mostly in the form of metastases. A primary neuroendocrine tumor in the liver concomitantly with hepatocellular carcinoma is an infrequent phenomenon. We present a 66-year-old woman with a remote history of breast cancer coming with postprandial fullness, later found to have multiple liver masses. After a thorough investigation, she was found to have a combined type of hepatocellular and primary neuroendocrine tumor of liver with pulmonary metastases. She was not a surgical candidate due to distant metastases. She was treated with chemotherapy, immunotherapy, and targeted therapies but continued to deteriorate clinically, and finally succumbed to her illness. The presence of this combined type of tumor in our patient is unique in many different ways: It is extremely rare, she did not have any risk factors for liver cancer, no genetic mutation till date could tie all these cancers (breast cancer, neuroendocrine tumor, and hepatocellular carcinoma) together, and not a lot of literatures/studies performed on this illness.

• breast cancer
• hepatocellular carcinoma
• primary neuroendocrine tumor of liver

Background: Neuroendocrine tumors are heterogeneous malignancies that originate from the neuroendocrine system. Previous studies show that this cancer type mainly localizes in the gastrointestinal tract and often metastasizes to the liver. Primary liver neuroendocrine tumors are very rare and primary hepatic neuroendocrine tumors (PHNET) with concurrent hepatocellular carcinoma (HCC) are extremely rare. To the best of our knowledge, only few PHNET cases have been identified, making their diagnosis difficult. Here, we report the biggest ever reported and “deceiving” lesion of a mixed neuroendocrine-non-neuroendocrine neoplasm in the liver, aiming to raise awareness and improve treatment of the disease.

Case Presentation: Here, we report a preoperative misdiagnosed case that presented with hepatocellular carcinoma clinical features and no extrahepatic tumors. Postoperative pathology confirmed that it was a mixed neuroendocrine-non-neuroendocrine neoplasm. The patient was then referred for etoposide and cisplatin-based chemotherapy. No disease recurrence was observed at the 6-month follow-up.

Conclusion: We report a very rare and easily misdiagnosed case and we speculate that there were “undifferentiated cells” undergoing neuroendocrine and hepatocellular carcinoma differentiation, during which some hepatocellular carcinoma cells express neuroendocrine features. We recommend proper surgery and postoperative platinum-based chemotherapy in the management of this disease.

• HCC
• case reports
• heterogeneous malignancies
• neuroendocrine tumor
• primary hepatic neuroendocrine tumor

Liver tumors with dual differentiations [combined hepatocellular carcinoma (HCC) and cholangiocarcinoma] are common. However, liver tumors that exhibit hepatocellular, biliary, and neuroendocrine differentiation are exceedingly rare, with only three previous case reports in the literature.

A 65-year-old female with a previous history of hepatitis C and a distant history of low grade, well-differentiated rectal neuroendocrine tumor was found to have two liver lesions in segment 4 and segment 7 on imaging. Serum alpha-fetoprotein and chromogranin A were elevated. Biopsy of the larger lesion in segment 4 revealed a high-grade tumor, with morphologic and immunohistochemical features of a neuroendocrine tumor. Given the previous history of rectal neuroendocrine tumor, imaging investigation, serologic markers, and biopsy findings, metastatic neuroendocrine tumor was considered. Subsequent regional resection of these hepatic lesions revealed the segment 4 lesion to be a HCC with additional biliary and neuroendocrine differentiation and the segment 7 lesion to be a cholangiocarcinoma with neuroendocrine differentiation. Follow-up of the patient revealed disease recurrence in the dome of the liver and metastasis in retro-pancreatic lymph nodes. The patient eventually expired due to complications of chemotherapy.

HCC cases with additional biliary and neuroendocrine differentiation are exceedingly rare, posing a diagnostic challenge for clinicians and pathologists.

• Mixed liver tumor
• Hepatocellular
• Biliary
• Neuroendocrine
• Triple differentiation
• Case report

Hepatocellular carcinoma (HCC) can grow in a mosaic pattern, often combined with various non-hepatocellular cells. However, HCC combined with a neuroendocrine carcinoma (NEC) component is rarely reported, and its clinical features, origin, diagnosis, and behavior have not been established. In the literature, mixed HCC–NEC tumors are categorized as either collision type or combined type, depending on their microscopic features. Here, we report a patient with a combined-type HCC–NEC tumor.

An asymptomatic 84-year-old woman was found to have a solid mass in the right lobe of the liver. Laboratory and radiologic examinations showed typical findings of HCC, including arterial-phase enhancement, and portal- and delay-phase washout. She was treated by partial laparoscopic hepatectomy of segment 5. Pathological examination showed that the tumor was predominantly HCC, partly admixed with an NEC component. A transitional zone between the HCC and NEC tissues was also observed. The tumor was finally diagnosed as a combined-type primary mixed NEC–HCC tumor. After the preoperative diagnosis, the patient underwent somatostatin receptor scintigraphy to detect the primary NEC lesion, but no accumulation was found in any other part of her body. She has been free of recurrence for 9 months since the surgery.

Mixed HCC–NEC tumors are extremely rare, and correct diagnosis requires multidisciplinary collaboration. The accumulation of further cases is needed to help understand the exact pathology, diagnosis, and treatment of this disease.

• Hepatocellular carcinoma
• Mixed neuroendocrine neoplasm
• Neuroendocrine carcinoma

• MANEC
• MiNEN
• classification
• mixed neuroendocrine and non-neuroendocrine neoplasm
• prognosis

• Collision tumor
• Combined tumor
• High malignancy
• Operation
• Rare disease

• case report
• cholangiocarcinoma
• collision carcinoma
• primary hepatic neuroendocrine carcinoma

• CD56 Antigen/analysis
• CD56 Antigen/blood
• Carcinoma, Neuroendocrine/diagnosis
• Carcinoma, Neuroendocrine/pathology
• Cholangiocarcinoma/diagnosis
• Cholangiocarcinoma/pathology
• Chromogranin A/analysis
• Chromogranin A/blood
• Female
• Humans
• Immunohistochemistry/methods
• Liver/abnormalities
• Liver/pathology
• Liver/physiopathology
• Middle Aged
• Prognosis
• Synaptophysin/analysis
• Synaptophysin/blood
• Tomography, X-Ray Computed/methods

• Hepatocellular carcinoma
• Liver neoplasm
• Neuroendocrine carcinoma

• liver
• neuroendocrine neoplasm
• primary

• Adult
• Aged
• Aged, 80 and over
• Antigens, Tumor-Associated, Carbohydrate/blood
• Female
• Hepatectomy/methods
• Hepatectomy/statistics & numerical data
• Humans
• Liver Neoplasms/mortality
• Liver Neoplasms/pathology
• Liver Neoplasms/surgery
• Male
• Middle Aged
• Neoplasm Grading
• Neoplasm Recurrence, Local
• Neuroendocrine Tumors/mortality
• Neuroendocrine Tumors/pathology
• Neuroendocrine Tumors/surgery
• Operative Time
• Prognosis
• Retrospective Studies
• Risk Factors
• Survival Rate

• Carcinoma, hepatocellular
• Carcinoma, neuroendocrine
• Liver
• Combined

Primary hepatic neuroendocrine carcinomas are extremely rare. Because of the rarity of PHNEC, its clinical features and treatment outcomes are not well understood. A proper diagnosis and the correct therapeutic approach therefore remain clinically challenging.

A 67-year-old man was admitted to our department because of a liver tumor. Computed tomography revealed a single liver tumor 50 mm in diameter and located in the S3 region. Biopsy and imaging findings resulted in a diagnosis of primary hepatic neuroendocrine carcinoma. Left lateral segmentectomy was performed. Immunohistochemically, the tumor cells were positive for synaptophysin, chromogranin A, and CD56. Ki-67 was positive in > 90% of the tumor cells. The final diagnosis was primary hepatic neuroendocrine carcinoma. The patient suffered two episodes of lymph node recurrence. Nonetheless, the tumor was excised to prolong survival. Thus, after lymphadenectomy, he received adjuvant chemotherapy for 6 months. Two years after surgery, the patient remains alive and in good general condition.

In most cases, primary hepatic neuroendocrine carcinoma, while extremely rare, has a poor prognosis. At present, surgical resection is a priority for curative treatment, but in patients with recurrence, combined therapies are recommended.

• Hepatectomy
• Liver resection
• Primary hepatic neuroendocrine carcinoma

• composite tumor
• hepatocellular carcinoma
• neuroendocrine carcinoma
• neuroendocrine tumor
• nodal metastasis
• small cell carcinoma

• Aged
• Carcinoma, Hepatocellular/complications
• Carcinoma, Hepatocellular/pathology
• Carcinoma, Hepatocellular/surgery
• Carcinoma, Small Cell/complications
• Carcinoma, Small Cell/pathology
• Carcinoma, Small Cell/surgery
• Hepatectomy
• Hepatitis C, Chronic/complications
• Humans
• Liver Neoplasms/complications
• Liver Neoplasms/pathology
• Liver Neoplasms/surgery
• Lymphatic Metastasis
• Male

• Hepatic
• Liver
• Liver resection
• Neuroendocrine tumor

• Adult
• Biomarkers, Tumor/analysis
• Biopsy
• Carcinoma, Neuroendocrine/chemistry
• Carcinoma, Neuroendocrine/pathology
• Carcinoma, Neuroendocrine/surgery
• Hepatectomy
• Humans
• Immunohistochemistry
• Liver Neoplasms/chemistry
• Liver Neoplasms/pathology
• Liver Neoplasms/surgery
• Magnetic Resonance Imaging
• Male
• Tomography, X-Ray Computed
• Treatment Outcome

• Hepatitis B
• Hepatocellular carcinoma
• Liver cirrhosis
• Neuroendocrine carcinoma

Undifferentiated carcinoma (UC) of the liver is extremely rare, and its clinicopathological characteristics have not been fully elucidated.

The present study reports the case of a 56-year-old male with UC of the liver. At 16 days post-admission, the patient suddenly succumbed due to intra-abdominal bleeding resulting from a ruptured liver. Macroscopic examination revealed that the hepatic parenchyma was almost completely replaced by innumerable minute nodules. Microscopically, the tumor demonstrated a diffuse proliferation of anaplastic cells that were positive for epithelial membrane antigen and neuron-specific enolase, suggesting neuroendocrine differentiation. Grimelius and Fontana-Masson staining were negative. Neuroendocrine markers were also negative, including chromogranin A, synaptophysin, and S-100 protein. Cytokeratin markers and mesenchymal markers were all negative. Tumor markers, such as α-fetoprotein and carcinoembryonic antigen, were also negative.

Although larger studies involving more patients are required to establish a therapeutic strategy, appropriate chemotherapy following an early diagnosis may be important to UC of the liver because the tumor behaves in an aggressive way.

• Liver cancer
• Neuroendocrine carcinoma
• Undifferentiated carcinoma

• Classification
• Combined tumor
• Composite tumor
• Mixed adenoneuroendocrine carcinoma
• Mixed neoplasm
• Neuroendocrine

• Female
• Humans
• Immunohistochemistry
• Male
• Neoplasms, Complex and Mixed/classification
• Neuroendocrine Tumors/classification

• CARCINOID
• LIVER CANCER
• Neuroendocrine

Primary hepatic neuroendocrine carcinoma (NEC) with concurrent occurrence of hepatocellular carcinoma (HCC) of the liver is very rare. Only 8 cases have been reported in the literature. Concurrent occurrence of HCC and NEC in the liver is classified as combined type or collision type by histological distributional patterns; only 2 cases have been reported. Herein, we report a case of collision type concurrent occurrence of HCC and NEC, in which primary hepatic NEC was in only a small portion of the nodule, which is different from the 2 previously reported cases. A 72-year-old male with chronic hepatitis C was admitted to our hospital for a hepatic mass detected by liver computed tomography (CT) at another clinic. Because the nodule was in hepatic segment 3 and had proper radiologic findings for diagnosis of HCC, including enhancement in the arterial phase and wash-out in the portal and delay phases, the patient was treated with laparoscopic left lateral sectionectomy. The pathology demonstrated that the nodule was 2.5 cm and was moderately differentiated HCC. However, a 3 mm-sized focal neuroendocrine carcinoma was also detected on the capsule of the nodule. The tumor was concluded to be a collision type with HCC and primary hepatic NEC. After the surgery, for follow-up, the patient underwent a liver CT every 3 mo. Five multiple nodules were found in the right hepatic lobe on the follow-up liver CT 6 mo post-operatively. As the features of the nodules in the liver CT and MRI were different from that of HCC, a liver biopsy was performed. Intrahepatic recurrent NEC was proven after the liver biopsy, which showed the same pathologic features with the specimen obtained 6 mo ago. Palliative chemotherapy with a combination of etoposide and cisplatin has been administered for 4 months, showing partial response.

• Collision tumor
• Hepatocellular carcinoma
• Neuroendocrine carcinoma
• Chronic hepatitis C

• Aged
• Antineoplastic Combined Chemotherapy Protocols/therapeutic use
• Biopsy
• Carcinoma, Hepatocellular/pathology
• Carcinoma, Hepatocellular/surgery
• Carcinoma, Neuroendocrine/pathology
• Carcinoma, Neuroendocrine/surgery
• Hepatectomy/methods
• Humans
• Immunohistochemistry
• Laparoscopy
• Liver Neoplasms/pathology
• Liver Neoplasms/surgery
• Magnetic Resonance Imaging
• Male
• Neoplasm Recurrence, Local
• Neoplasms, Multiple Primary
• Palliative Care
• Treatment Outcome

• 68Ga-DOTATOC
• Combined tumor
• Hepatocellular carcinoma
• Neuroendocrine carcinoma

• Aged
• Carcinoma, Hepatocellular/diagnostic imaging
• Carcinoma, Hepatocellular/pathology
• Carcinoma, Hepatocellular/surgery
• Carcinoma, Neuroendocrine/diagnostic imaging
• Carcinoma, Neuroendocrine/pathology
• Carcinoma, Neuroendocrine/surgery
• Hepatectomy/methods
• Humans
• Liver Neoplasms/diagnostic imaging
• Liver Neoplasms/pathology
• Liver Neoplasms/surgery
• Magnetic Resonance Imaging
• Male
• Neoplasms, Multiple Primary/diagnostic imaging
• Neoplasms, Multiple Primary/pathology
• Neoplasms, Multiple Primary/surgery
• Positron Emission Tomography Computed Tomography
• Tomography, X-Ray Computed

The present study aimed to analyze the imaging features and pathological basis of primary hepatic neuroendocrine carcinoma (PHNEC). A retrospective analysis of the imaging and pathological features of nine PHNEC cases was carried out at The Second Xiangya Hospital of Central South University (Changsha, China). The nine patients were subjected to dynamic contrast-enhanced computed tomography (CT) scanning of the liver and pathological diagnosis of the tissue samples. In addition, two patients were subjected to magnetic resonance imaging (MRI). CT scanning revealed the presence of single or multiple masses in the liver with a maximum diameter of 1–10 cm. These hepatic masses were of low density as showed by plain CT. These masses showed uneven or annular enhancement at their margins in the arterial phase. The venous portal phase showed consistent or declined enhancement and the delayed phase showed light enhancement in these masses. In addition, multiple intrahepatic nodules with long T1 and T2 signal intensities and obvious enhancement were observed by MRI in one patient, while intrahepatic lesions with moderate length T2 signal intensities and light enhancement not visible on the T1 image were observed in another patient. Pathological analysis revealed that the tumor cells exhibited morphological diversity. Immunohistochemical staining revealed that the tumor cells were chromogranin A- and synaptophysin-positive, and carcinoembryonic antigen-, hepatocytic antigen- and α-fetoprotein-negative. Imaging methods, including CT and MRI, are useful for the diagnosis of PHNEC; however, pathological examination is required for a final, definite diagnosis.

• computed tomography
• magnetic resonance imaging
• pathology
• primary hepatic neuroendocrine carcinoma

• Hepatocellular carcinoma
• Neuroendocrine tumor
• Right hepatectomy

A 67-year-old woman was admitted to our hospital under suspicion of a hepatic tumor, which had been previously diagnosed to be an adenocarcinoma by fine needle aspiration. Computed tomography and magnetic resonance imaging revealed a large tumor measuring 9 cm in diameter in Couinaud's hepatic segments 4, 5, and 8. We diagnosed the patient to have primary liver cancer, and suspected intrahepatic cholangiocarcinoma preoperatively. We performed a central hepatectomy. According to the immunohistochemical findings of the resected specimen, the tumor was diagnosed to be a primary neuroendocrine carcinoma in the liver. The patient is presently alive without recurrence at 3 months after hepatic resection.

• Chromogranin A
• Hepatectomy
• Liver malignancy
• Neuroendocrine carcinoma

Primary hepatic neuroendocrine tumors (PHNETs) are rear neoplasm. Diagnosis is an evolution, and requires a systematic clinical exclusion with histological confirmation. Treatment is surgical with excellent prognosis, and a long-term follow-up is required due to high tumor recurring rate. Knowledge from this species of tumor remains limited due to paucity of cases. This article elaborates the key features, diagnosis algorithm, current management, other treatment options and extensive review of literature on this rear tumor.

• Carcinoid
• Liver
• Neuroendocrine tumor
• Primary hepatic tumor

• Carcinoma, Neuroendocrine/pathology
• Carcinoma, Neuroendocrine/surgery
• Female
• Hepatectomy
• Humans
• Liver Neoplasms/pathology
• Liver Neoplasms/surgery
• Middle Aged

We describe a rare hepatic collision tumor composed of a hepatocellular carcinoma and a high-grade neuroendocrine carcinoma. The patient, a 68-year-old man, underwent a partial hepatectomy because of a 4.0 cm mass. The tumor had two distinctive patterns. The majority of the tumor was a high-grade neuroendocrine carcinoma with features of a small cell carcinoma that was positive for chromogranin, synaptophysin, and cytokeratin 19 and negative for hepatocellular antigen and alpha-fetoprotein (AFP). The second component was a moderately differentiated hepatocellular carcinoma that was positive for hepatocellular antigen and AFP and negative for neuroendocrine markers. The two tumors were separated by fibrous bands. In areas where they collided, there was no transition or intermingling of cells between the two components, thus, it is different from the combined type of tumors. After removal of the tumor, the patient underwent four courses of chemotherappy which included etoposide and cisplatin with a follow-up period of 28 months.

• Hepatocellular carcinoma
• Liver tumors
• Neuroendocrine carcinoma

• Aged
• CD56 Antigen/analysis
• Carcinoma, Hepatocellular/pathology
• Carcinoma, Neuroendocrine/pathology
• Humans
• Ki-67 Antigen/analysis
• Liver Neoplasms/pathology
• Male

• Aged
• Autopsy
• Biomarkers, Tumor/analysis
• Carcinoma, Neuroendocrine/complications
• Carcinoma, Neuroendocrine/metabolism
• Carcinoma, Neuroendocrine/pathology
• Dermatomyositis/complications
• Dermatomyositis/pathology
• Humans
• Immunohistochemistry
• Liver Neoplasms/complications
• Liver Neoplasms/metabolism
• Liver Neoplasms/pathology
• Male
• Paraneoplastic Syndromes/complications
• Paraneoplastic Syndromes/pathology

• Biomarkers, Tumor/analysis
• Carcinoma, Hepatocellular/chemistry
• Carcinoma, Hepatocellular/pathology
• Carcinoma, Hepatocellular/surgery
• Carcinoma, Neuroendocrine/chemistry
• Carcinoma, Neuroendocrine/pathology
• Carcinoma, Neuroendocrine/surgery
• Chromogranins/analysis
• Humans
• Immunoenzyme Techniques
• Keratin-19/analysis
• Liver Neoplasms/chemistry
• Liver Neoplasms/pathology
• Liver Neoplasms/surgery
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Neoplasms, Multiple Primary
• Synaptophysin/analysis